Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Brain Neoplasms 3Carcinoma, Hepatocellular 2Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Leiomyoma 1Glioma 1Fibroadenoma 1Colorectal Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Breast Diseases 1

Interventions

Tamoxifen 25Radiotherapy 15Chemotherapy, Adjuvant 11Anastrozole 11Specimen Handling 10Neoadjuvant Therapy 8Letrozole 8Biopsy 7Radiation 6Mastectomy, Segmental 6Magnetic Resonance Spectroscopy 6Immunohistochemistry 5Gene Expression Profiling 5exemestane 4Surgical Procedures, Operative 4Sentinel Lymph Node Biopsy 4Radiotherapy, Intensity-Modulated 4Radiotherapy, Conformal 4Psychiatric Rehabilitation 4Mass Spectrometry 4Early Intervention, Educational 4Counseling 4afimoxifene 3Trastuzumab 3Surveys and Questionnaires 3Reverse Transcriptase Polymerase Chain Reaction 3Radiation Dose Hypofractionation 3Methods 3Mastectomy 3High-Energy Shock Waves 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Intraductal, Noninfiltrating × gadoterate meglumine × Clear all
NCT04341129 2023-12-05

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

University of Chicago

Phase EARLY_PHASE1 Completed
50 enrolled
Breast

Breast Diseases, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Fibroadenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡